Baclofen Effects in Cigarette Smokers

NCT01821560 | Completed Phase 2 Results

• 3 other identifiers: 817101R01DA030394-01A1PA Depart of Health
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.

Conditions

Nicotine Dependence

Keywords

Nicotine Addiction; fMRI; Baclofen

Outcome Measures

Primary Outcomes (1)

• Cigarettes Smoked Per Day

  Cigarettes per day at Scan Day 2; Baclofen group vs. placebo group

  3 weeks (Scan Day 1, week1- Scan Day 2, week 4)

Study Arms (2)

Sugar pill

PLACEBO COMPARATOR

Placebo-treated subjects will follow the identical schedule as Baclofen subjects.

Drug: placebo

Baclofen

ACTIVE COMPARATOR

Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.

Drug: Baclofen

Interventions

Baclofen DRUG

Also known as: Kemstro, Lioresal, Liofen, Gablofen, Beklo

Baclofen

placebo DRUG

Sugar pill

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Physically healthy, as determined by a comprehensive physical examination and approval of the study physician males or females who smoke cigarettes, ages 18-60.
• Smoke ≥ 6 cigarettes per day for at least 6 months prior to study start date.
• Females must be non-pregnant, non-lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 1 year post-menopausal) or of child bearing potential but practicing a medically acceptable method of birth control. Examples of medically acceptable methods for this protocol include barrier (diaphragm or condom) with spermicide, an intrauterine device (IUD), the Nuvaring, oral contraceptives, levonorgestrel implant, hormonal injection or complete abstinence.
• Provide voluntary informed consent.
• Must be able to read. \[Subjects are required to be able to read because there are several self-administered measures that they must read, understand and provide written answers.\]
• Intelligence quotient of ≥ 80.

You may not qualify if:

• History of head trauma or injury causing loss of consciousness, lasting more than five (5) minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI.
• Current Diagnostic and Statistical Manual-IV (DSM-IV) Axis I diagnoses other than nicotine dependence.
• Presence of magnetically active irremovable prosthetics, plates, pins, permanent retainer, bullets, etc. (unless a radiologist confirms that it's presence is unproblematic). An x-ray may be obtained to determine eligibility given the possibility of a foreign body.
• History of psychosis.
• Claustrophobia or other medical condition preventing subject from lying in the MRI for approximately one (1) hour.
• Current diagnosis of or treatment within the last 3 months for alcohol dependence.
• Current use of any smoking cessation treatments such as Zyban, Chantix, Wellbutrin, patch, gum, inhaler, electronic cigarettes, herbal preparations.
• Vision problems that cannot be corrected with glasses.
• Weight exceeding 300 pounds \[Imaging data acquisition is impaired with high weight individuals\].
• History of stroke.

Sponsors & Collaborators

• University of Pennsylvania: lead
• National Institute on Drug Abuse (NIDA): collaborator
• National Institutes of Health (NIH): collaborator

Study Sites (1)

University of Pennsylvania Center for Studies of Addiction

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Tobacco Use Disorder

Interventions

Baclofen

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric Acid; Aminobutyrates; Butyrates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals

Limitations and Caveats

The goals of the study were to identify mechanisms of baclofen's effects on smoking cue reactivity. Using other mechanisms we provided a treatment arm. Sample size was small.

Results Point of Contact

• Title: Dr. Teresa R. Franklin
• Organization: University of Pennsylvania

teresafr@pennmedicine.upenn.edu

215-746-1883

Study Officials

• Teresa R Franklin, Ph.D.

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 21, 2013
• First Posted: April 1, 2013
• Study Start: March 1, 2013
• Primary Completion: June 1, 2017
• Study Completion: June 1, 2017
• Last Updated: December 19, 2018
• Results First Posted: December 19, 2018

Record last verified: 2018-11

Locations

US (1)